Home
|
Contact
|
Imprint
|
Sitemap
|
Privacy notice
Toggle navigation
Home
About AiCuris
Company Profile
Management Team
Holger Zimmermann
Holger Schmoll
Alexander Birkmann
Helmut Buschmann
Manickam Rangaraju
Silvia Riffel-Friedrich
Scientific Advisory Board
Helga Rübsamen-Schaeff
Mark Wilcox
Per Ljungman
Memberships
PREP
PREP
AIC649 in Corona
AMR
AiCubator
Partnering & Licensing
Research & Development
Strategy
R&D Pipeline
Projects Overview
HCMV - Letermovir
HSV - Pritelivir (AIC316)
HBV - AIC649
Adenovirus - Research
Bacteriology - Research
Pritelivir Early Access
Research Tools & Services
Partnering & Licensing
AiCuris & Partnering
Partnering Opportunities
Pritelivir (AIC316)
AIC649
In-Licensing & Collaborations
AiCubator
News & Media
Press releases
2021
2020
2019
2018
2017 and before
Services for Press
Deutscher Zukunftspreis - 2018 Award Winners
EFPIA Disclosure Code
Career
Join AiCuris
Employee Benefits
Job Opportunities
Privacy Notice for applicants
Contact
Directions
Company Profile
Management Team
Holger Zimmermann
Holger Schmoll
Alexander Birkmann
Helmut Buschmann
Manickam Rangaraju
Silvia Riffel-Friedrich
Scientific Advisory Board
Helga Rübsamen-Schaeff
Mark Wilcox
Per Ljungman
Memberships
Dr. Holger Zimmermann
Chief Executive Officer (CEO)
Holger Schmoll
Chief Financial Officer (CFO)
Dr. Alexander Birkmann
Head of Research
Dr. Helmut Buschmann
Head of Chemistry, Pharmaceutical Development and Patent Affairs
Dr. Manickam Rangaraju
Head of Development
Silvia Riffel-Friedrich
Head of Regulatory Affairs & Compliance
×
Close
